Basilea Raises FY26 Income Guidance to CHF 250M, Lifts 2030 Cash Target
Basilea raised FY26 guidance for Cresemba- and Zevtera-related income to CHF 250M, 19% above its prior guidance, and increased its cumulative cash flow target through 2030 to CHF 650M. The company also outlined streamlined plans for ceftibuten-ledaborbactam and reported progress in fosmanogepix Phase 3.
Basilea raised FY26 guidance for Cresemba and Zevtera-related income to CHF 250M, 19% above prior, and lifted its Agenda 2030 cumulative cash flow target to CHF 650M. It also outlined streamlined plans for ceftibuten-ledaborbactam and progress in fosmanogepix phase 3.Material DetailsContext by AI A…